期刊
MELANOMA RESEARCH
卷 21, 期 2, 页码 152-159出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CMR.0b013e328343ece0
关键词
cytotoxic T-lymphocyte antigen 4; dendritic cell vaccine; equilibrium; immunotherapy; ipilimumab; melanoma
资金
- Willy Gepts Wetenschappelijk Fonds of the UZ Brussel
Metastatic melanoma runs a predictable detrimental course in the vast majority of patients. New modalities of immunotherapy, such as melanoma antigen-specific therapeutic vaccination and cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor blockade by monoclonal antibodies (mAbs), have been associated with atypical kinetics of tumor response that differ from those observed during cytotoxic treatment. Recently, new tumor response criteria have been proposed based on the tumor response characteristics observed in clinical studies with ipilimumab (the so-called 'immune-related response criteria'). We report three illustrative cases of the American Joint Committee on Cancer stage IV-M1c melanoma patients who experienced atypical kinetics of tumor response to the treatment with the CTLA-4-blocking mAb, ipilimumab (case 1), or an autologous dendritic cell vaccine in combination with interferon alpha-2b (cases 2 and 3). These cases show that atypical response patterns not only relate to the outcome of CTLA-4-blocking mAb therapy but also to the treatment with therapeutic vaccines and interferon alpha-2b. Melanoma Res 21:152-159 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据